Calliditas Therapeutics
Calliditas Year-end report, January - December 2023
REG
OCTOBER - DECEMBER 2023(COMPARED TO OCTOBER - DECEMBER 2022)
|
JANUARY - DECEMBER 2023(COMPARED TO JANUARY -DECEMBER 2022)
|
"In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN."
CEO Renée Aguiar-Lucander
KEY TAKEAWAYS FROM Q4, 2023
|
EXPECTED KEY EVENTS UPCOMING 6 MONTHS
|
OUTLOOK FOR 2024
Calliditas expects continued revenue growth:
Total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024
INVESTOR PRESENTATION
February 21, 2024, 14:30 CET
Link to webcast: https://ir.financialhearings.com/calliditas-therapeutics-q4-report-2023
To participate via conference call register via this link: https://conference.financialhearings.com/teleconference/?id=50046870
Datum | 2024-02-21, kl 07:00 |
Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!